Cargando…

JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats

We investigated the effects of JTT-130 on glucose and lipid metabolism independent of the suppression of feeding by comparing with pair-fed animals. Male Zucker diabetic fatty (ZDF) rats were divided into control, JTT-130 treatment, and pair-fed groups. The rats were fed with a regular powdered diet...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakata, Shohei, Ito, Makoto, Mera, Yasuko, Sasase, Tomohiko, Yamamoto, Hiromi, Kakutani, Makoto, Ohta, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033514/
https://www.ncbi.nlm.nih.gov/pubmed/24895641
http://dx.doi.org/10.1155/2014/803832
_version_ 1782317831240548352
author Sakata, Shohei
Ito, Makoto
Mera, Yasuko
Sasase, Tomohiko
Yamamoto, Hiromi
Kakutani, Makoto
Ohta, Takeshi
author_facet Sakata, Shohei
Ito, Makoto
Mera, Yasuko
Sasase, Tomohiko
Yamamoto, Hiromi
Kakutani, Makoto
Ohta, Takeshi
author_sort Sakata, Shohei
collection PubMed
description We investigated the effects of JTT-130 on glucose and lipid metabolism independent of the suppression of feeding by comparing with pair-fed animals. Male Zucker diabetic fatty (ZDF) rats were divided into control, JTT-130 treatment, and pair-fed groups. The rats were fed with a regular powdered diet with or without JTT-130 as a food admixture for 6 weeks. We compared the effects on glucose and lipid metabolism in JTT-130 treatment group with those in pair-fed group. Results. Hyperglycemia in ZDF rats was prevented in both JTT-130 treatment and pair-fed groups, but the prevention in pair-fed group became poor with time. Moreover, reduction in plasma cholesterol levels was observed only in JTT-130 treatment group. JTT-130 treatment group showed improved glucose tolerance at 5 weeks after treatment and significant elevation of portal glucagon-like peptide-1 (GLP-1) levels. The hepatic lipid content in JTT-130 treatment group was decreased as compared with pair-fed group. Furthermore, pancreatic protection effects, such as an increase in pancreatic weight and an elevation of insulin-positive area in islets, were observed after JTT-130 treatment. Conclusions. JTT-130 improves hyperglycemia and dyslipidemia via a mechanism independent of suppression of food intake, which is ascribed to an enhancement of GLP-1 secretion and a reduction of lipotoxicity.
format Online
Article
Text
id pubmed-4033514
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40335142014-06-03 JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats Sakata, Shohei Ito, Makoto Mera, Yasuko Sasase, Tomohiko Yamamoto, Hiromi Kakutani, Makoto Ohta, Takeshi J Diabetes Res Research Article We investigated the effects of JTT-130 on glucose and lipid metabolism independent of the suppression of feeding by comparing with pair-fed animals. Male Zucker diabetic fatty (ZDF) rats were divided into control, JTT-130 treatment, and pair-fed groups. The rats were fed with a regular powdered diet with or without JTT-130 as a food admixture for 6 weeks. We compared the effects on glucose and lipid metabolism in JTT-130 treatment group with those in pair-fed group. Results. Hyperglycemia in ZDF rats was prevented in both JTT-130 treatment and pair-fed groups, but the prevention in pair-fed group became poor with time. Moreover, reduction in plasma cholesterol levels was observed only in JTT-130 treatment group. JTT-130 treatment group showed improved glucose tolerance at 5 weeks after treatment and significant elevation of portal glucagon-like peptide-1 (GLP-1) levels. The hepatic lipid content in JTT-130 treatment group was decreased as compared with pair-fed group. Furthermore, pancreatic protection effects, such as an increase in pancreatic weight and an elevation of insulin-positive area in islets, were observed after JTT-130 treatment. Conclusions. JTT-130 improves hyperglycemia and dyslipidemia via a mechanism independent of suppression of food intake, which is ascribed to an enhancement of GLP-1 secretion and a reduction of lipotoxicity. Hindawi Publishing Corporation 2014 2014-05-07 /pmc/articles/PMC4033514/ /pubmed/24895641 http://dx.doi.org/10.1155/2014/803832 Text en Copyright © 2014 Shohei Sakata et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sakata, Shohei
Ito, Makoto
Mera, Yasuko
Sasase, Tomohiko
Yamamoto, Hiromi
Kakutani, Makoto
Ohta, Takeshi
JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats
title JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats
title_full JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats
title_fullStr JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats
title_full_unstemmed JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats
title_short JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Improves Hyperglycemia and Dyslipidemia Independent of Suppression of Food Intake in Diabetic Rats
title_sort jtt-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, improves hyperglycemia and dyslipidemia independent of suppression of food intake in diabetic rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033514/
https://www.ncbi.nlm.nih.gov/pubmed/24895641
http://dx.doi.org/10.1155/2014/803832
work_keys_str_mv AT sakatashohei jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats
AT itomakoto jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats
AT merayasuko jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats
AT sasasetomohiko jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats
AT yamamotohiromi jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats
AT kakutanimakoto jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats
AT ohtatakeshi jtt130anovelintestinespecificinhibitorofmicrosomaltriglyceridetransferproteinimproveshyperglycemiaanddyslipidemiaindependentofsuppressionoffoodintakeindiabeticrats